Top Aging Scientists Gather at Harvard to Advance Biomarkers of Aging
The 2026 Biomarkers of Aging Conference unites leading researchers, regulators, and funders to validate tools for measuring biological aging.
Summary
The Biomarkers of Aging Consortium is hosting its fourth annual conference on October 5–6, 2026, at Harvard Medical School. Nearly 30 speakers from academia, industry, and regulatory agencies will convene to advance the science of measuring biological aging. Key topics include epigenetic clocks, AI-driven aging models, multi-omic profiling, immune aging, and how biomarkers can support clinical trials of longevity therapies. Notable speakers include Steve Horvath, Dan Belsky, Vera Gorbunova, and Morgan Levine. Satellite programs on brain aging and reproductive aging extend the week's programming. The overarching goal is standardizing how biological aging is measured so that interventions targeting aging itself can be reliably tested and eventually approved.
Detailed Summary
Biomarkers of aging are among the most critical tools in longevity science — without them, researchers cannot reliably determine whether a drug, supplement, or lifestyle intervention actually slows or reverses biological aging. The 2026 Biomarkers of Aging Conference, hosted by the Biomarkers of Aging Consortium at Harvard Medical School, brings together close to 30 world-leading scientists, clinicians, industry figures, and regulators to tackle exactly this challenge.
The program covers the full landscape of aging measurement. Epigenetic clock pioneers Steve Horvath and Dan Belsky will present on DNA methylation-based aging clocks including DunedinPACE, a tool that captures the pace of biological aging rather than just a static age estimate. Systems and mathematical perspectives come from Uri Alon, Albert-László Barabási, and Michael Levin, while Vera Gorbunova, Thomas Rando, and Mike Snyder address mechanisms of aging through long-lived species biology, stem cell aging, and longitudinal multi-omic human profiling.
Industry representatives Morgan Levine and Martin Borch Jensen are developing AI models and causal atlases of age-related disease — approaches that could dramatically accelerate the identification and validation of reliable aging biomarkers. Regulatory and funding leaders from ARPA-H, the FDA, XPRIZE Healthspan, and Wellcome Leap will address the path from biomarker discovery to accepted clinical endpoints.
New for 2026, the conference includes satellite symposia on brain aging and reproductive aging, as well as a session dedicated to regenerative and replacement strategies. Conference chairs emphasize that speed of discovery must be matched by rigorous validation and stakeholder consensus before biomarkers can guide treatment decisions.
For health-conscious adults, the practical implication is clear: the tools used to measure whether longevity interventions work are being actively standardized, which will soon make it far easier to evaluate which anti-aging strategies genuinely move the biological needle.
Key Findings
- Epigenetic clocks like DunedinPACE can measure the pace of biological aging, not just a static age estimate.
- AI and causal biology approaches are being applied to identify reliable, validated aging biomarkers faster.
- FDA and major funders are actively engaged in defining how aging biomarkers qualify as clinical trial endpoints.
- Multi-omic longitudinal profiling of humans is emerging as a key strategy to discover and validate aging measures.
- Satellite symposia on brain aging and reproductive aging reflect growing specialization within the biomarker field.
Methodology
This is a news report and conference announcement from Lifespan.io, a credible longevity-focused science publication. It summarizes program content and quotes conference co-chairs but does not present original research data. Evidence basis is expert consensus and speaker credentials rather than peer-reviewed findings.
Study Limitations
This article is a conference preview, not a report of new research findings. No primary data, results, or peer-reviewed evidence are presented. Readers should consult published outputs from the featured researchers and await post-conference publications for concrete scientific advances.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: